Revised SPC: Perjeta (pertuzumab) concentrate for solution for infusion

SPC now states that the incidence of decreased appetite, anaemia, weight decreased, asthenia, dysgeusia, peripheral neuropathy, hypomagnesemia and diarrhoea in patients ≥ 65 years of age was at least 5% higher than in those <65 years.

Source:

electronic Medicines compendium